Medscape Education

Learning Centers

STOP AND THINK...
Could it be a rare disease?

Latest In Oncology

Filter

All U.S. Non-U.S.

0 global 1 0.5 9 0.5 0.5 Roundtable 0 1

Light-Chain Amyloidosis: Navigating Heterogeneous Patient Presentation, Swift Diagnosis, and Treatment Planning

Can you recognize light-chain amyloidosis in a patient? Start activity

Light-Chain Amyloidosis: Navigating Heterogeneous Patient Presentation, Swift Diagnosis, and Treatment Planning

View Details

0.5Credits 30 MIN

Breast Cancer 840 global 1 0.5 9 0.5 0.5 Roundtable 0 1

Managing the Borderline-Risk Patient With Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Shedding Light on the Role of Surgeon, Radiologist, and Oncologist

Do you consult with the multidisciplinary team (MDT) when making treatment decisions for patients with hormone receptor (HR)-positive/HER2-negative early breast cancer (EBC)? Start activity

Managing the Borderline-Risk Patient With Hormone Receptor-Positive/HER2-Negative Early Breast Cancer: Shedding Light on the Role of Surgeon, Radiologist, and Oncologist

View Details

0.5Credits 30 MIN

Atrial Fibrillation 390 global 1 0.5 9 0.5 2 0.5 3 0.5 0.5 Roundtable 0 1

Addressing Suboptimal Anticoagulation in Atrial Fibrillation: Uncoupling the Potential of Factor XI/XIa Inhibition for Stroke Prevention

Why target factor XI/XIa? Experts discuss the rationale, mechanism, and the latest phase 2 data. Start activity

Addressing Suboptimal Anticoagulation in Atrial Fibrillation: Uncoupling the Potential of Factor XI/XIa Inhibition for Stroke Prevention

View Details

0.5Credits 30 MIN

Breast Cancer 840 global 1 0.5 9 0.5 2 0.5 3 0.5 0.5 Roundtable 0 1

Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer: The Great Debate

What strategies are you using to individualize treatment of HR+/HER2- early breast cancer? Start activity

Navigating Between Endocrine Therapy, Chemotherapy, and CDK 4/6 Inhibitors for High-Risk HR+/HER2- Early Breast Cancer: The Great Debate

View Details

0.5Credits 30 MIN

Melanoma 65 global 1 1.0 9 1.0 1.0 Clinical Review 0 1

LAG-3 Inhibitors for Metastatic Melanoma: Exploring Perspectives of the Multidisciplinary Team

Are you familiar with how to incorporate lymphocyte-activation gene 3 (LAG-3) inhibition into the management of metastatic melanoma? Find out more here! Start activity

LAG-3 Inhibitors for Metastatic Melanoma: Exploring Perspectives of the Multidisciplinary Team

View Details

1.0Credits 60 MIN

Acute Leukemia 5005273 global 1 1.0 9 1.0 1.0 Journal Article 0 1

Fractionated vs Single-Dose Gemtuzumab Ozogamicin with Determinants of Benefit in Older Patients with AML: the UK NCRI AML18 Trial

In older patients with AML, fractionated gemtuzumab increased response depth but not toxicity and improved survival in allografted patients. Start activity

View Details

1.0Credits 60 MIN

View All

Curated Collections

Curated activities and resources from our partners and committee

View All

Topics

Credits

Format

Type